GovChime
Notice ID: 05496a754cbd41789b208e3b5a84963fPresolicitationArchived

Soterix Medical, Inc HD-IFS PRO 8 Channel Stimulator Purchase for HPSNS Lab

Archived on August 25, 2026. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
9:00 AM EDT
Posted
July 30, 2026
Notice type
Presolicitation
NAICS
541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH OLAO
Place of performance
Bethesda, 20892
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
75N98026Q00914
Notice ID
05496a754cbd41789b208e3b5a84963f

Description

General Information Document Type: Presolicitation Synopsis Number: 75N98026Q00914 Posted Date: July 30, 2026 Original Response Date: August 10, 2026 Current Response Date: August 10, 2026 Set Aside: N/A NAICS Code: 541715 Contracting Office Address National Institutes of Health (NIH), Office of the Director (OD) Office of Logistics and Operations (OLAO) Office of Acquisition and Logistics Management (OALM) Hospital and Laboratory Support Division 6701 Rockledge Drive Bethesda, MD 20817 Description INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: Soterix Medical, Inc Aspen Corporate Park 1480 US Highway 9 North, 204 Woodbridge, NJ 07095 NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 541715 with a Size Standard $1000. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01, March 13, 2026. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION Title: Soterix Medical, Inc HD-IFS PRO 8 Channel Stimulator Purchase for HPSNS Lab Background Information: Our overall program objective is to perform translational human subjects research that leads to the development of new therapeutic technologies for the rehabilitation of motor skill function following brain injury or stroke. Our previous work, as well as the work of other research groups in our field, has indicated that non-invasive stimulation of deeper brain structures such as the basal ganglia or hippocampus can facilitate learning of new motor skills and rehabilitation outcomes in stroke patients. This TIS system, will provide for the the first time, a new capability within the lab to target and modulate these deep brain structures with non-invasive brain stimulation. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by August 10, 2026 at 9:00 AM Eastern time and must reference solicitation number 75N98026Q00914. Responses may be submitted electronically to Mr. James Law, Contracting Officer at James.Law@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.”

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

LAW, JAMES B

Documents

No documents available.

Lifecycle

  1. 3
    Version 3PresolicitationArchivedCurrent

    Soterix Medical, Inc HD-IFS PRO 8 Channel Stimulator Purchase for HPSNS Lab

    Notice 05496a754cbd41789b208e3b5a84963f on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
The United States Department of Navy Medicine Research and Development Command (NMRDC) intends to award a sole source contract to, Illumina Inc., San Diego, CA. This notice is not a request for competitive proposals however If interested Government shall consider all responses. Illumina does not offer third party vendors. The NAICS code for this action is 541714. This requirement will be procured under the guidelines of FAR Part 12 Commercial Items. NMRC requires that all contractors doing business with the Acquisition Office must be registered with the Systems for Award Management (SAM). No award can be made unless the vendor is registered in Systems for Award Management. For additional information and to register in SAM, please access the following website: https://www.sam.gov/. In order to register with the SAM and to be eligible to receive an award from this Acquisition Office, all offers must have a Unique Entity Identification Number (UEI). A Sam.gov number may be acquired free of charge by contacting Sam.gov online at www.sam.gov or by phone at (866) 606-8220.
57%
Special Notice11/20/2026
SPECIAL NOTICE: VENDORS MUST REFERENCE THE NOTICE ID WHEN SUBMITTING A CAPABILITY STATEMENT. NASA/NSSC has a requirement for Support design and structural analysis for Hiwrap, MBARS, CRS and COSSIR instruments on the NASA WB57 aircraft. NASA/NSSC intends to issue a sole source contract to WELCH MECHANICAL DESIGNS, LLC 1200 Technology DR Suite N Aberdeen, Maryland 21001-1124 United States under the authority of FAR 12.102(a). It has been determined that WELCH MECHANICAL DESIGNS, LLC is the sole provider of Support design and structural analysis for Hiwrap, MBARS, CRS and COSSIR instruments on the NASA WB57 aircraft. NASA/NSSC will be the procuring center for this effort. Performance will be located at NASA/ Goddard Space Flight Center (GSFC). The Government intends to acquire Commercial items or services using the provisions, clauses and procedures prescribed in FAR Part 12 for Commercial The NAICS Code for this procurement is 541715. Interested organizations may submit their capabilities and qualifications to perform the effort in writing to the identified point of contact not later than 12:00 p.m. Central Standard Time on 11/9/2026. Such capabilities/qualifications will be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. A determination by the Government not to compete this proposed effort on a full and open competition basis, based upon responses to this notice, is solely within the discretion of the government. Oral communications are not acceptable in response to this notice. NOTE: Quotes received in response to this notice will NOT be considered and will not be evaluated by NASA’s Technical End User Team. We are currently only requesting Capability Statements. NASA FAR Supplement Clause 1852.215-84, Ombudsman, is applicable. The Center Ombudsman for this acquisition can be found at https://www.hq.nasa.gov/office/procurement/regs/Procurement-Ombuds-Comp-Advocate-Listing.pdf . Primary Point of Contact: (Note from Tiffany on Teams: When posting on SAM.GOV make sure you are adding the Contracting Officer as an alternate point of contact. ****REMOVE THIS SENTENCE PRIOR TO POSTING****
57%
Special Notice11/09/2026
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00038 /PCA-NIA-11810. This solicitation is issued as a competitive combined synopsis/solicitation for commercial products or commercial services. The Government intends to award a contract or purchase order resulting from this solicitation using full and open competition. This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold.
49%
Combined Synopsis12/08/2026
INTRODUCTION: The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the NIH, an agency within the Department of Health and Human Services (DHHS); conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten the health and longevity of human lives.Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical interventions against infectious disease threats to include drug-resistant pathogens. NIAID/DMID intends to use this BAA to help address goals articulated in a number of strategic plans, such as in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan (https://aspr.hhs.gov/PHEMCE/2024-PHEMCE-SIP/Pages/default.aspx), as well as current prioritized antimicrobial resistant threats identified by national death and infection estimates as determined by the Centers for Disease Control and Prevention’s (CDC) to prevent and control antimicrobial resistance (https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html). In addition, NIAID/DMID intends to use this BAA to encourage projects that align with the NIH priorities of enhancing rigor & reproducibility, improving biosafety and biosecurity, and the use of complementary non-animal testing methods where appropriate. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for infectious diseases in each of three (3) Research Areas described below and more thoroughly discussed in the attached BAA Solicitation. An offeror should carefully review the content of the BAA Solicitation No. HHS-NIH-NIAID-BAA2026-1 for the comprehensive information regarding all requirements, the technical objective of each Research Area of this BAA Solicitation, instructions regarding the proposal submission, and a description of the evaluation and award process. Please note, due to the competitive nature of the BAA Solicitation, the NIAID is unable to offer advice or feedback regarding an offeror’s specific technical approach. Offerors should exercise their professional judgment when compiling their proposals in line with the requirements and specifications of the BAA Solicitation. Research Area 001 - Vaccine Candidates: The objective is to develop vaccine candidates through an early phase clinical trial that use a needle free (i.e., alternative to classical needle and syringe, see below for description) route of delivery to protect against infections caused by viral pathogens that include but are not limited to respiratory and vector borne viruses. The scope of this vaccine research area includes the preclinical development of a needle free vaccine candidate, IND enabling studies, limited process development, Good Manufacturing Practice (GMP) compliant manufacturing, regulatory submissions to the U.S. Food and Drug Administration (FDA) and conduct of a Phase 1 or early Phase 2 clinical trial. The scope of work must include a clinical trial. Offerors must propose a single vaccine candidate for protection against a specific viral pathogen. The vaccine candidate may provide a breadth of protection against other viral strains or viruses. A strong justification is required to support (1) the proposed vaccine antigen and platform for the disease indication, (2) the use of a clinically relevant adjuvant (if needed), and (3) a clinically relevant needle free route of delivery. Research Area 002 - Therapeutic Candidates: The objective is to develop safe, effective, new therapeutic products that will improve patient outcomes against serious infectious diseases for which there are no approved therapeutics, or for those that are refractory to treatment despite appropriate antimicrobial therapy or due to pathogen resistance. Infectious diseases caused by the following viruses, bacteria and fungi pathogens are targeted: Viral hemorrhagic fever viruses (e.g., EBOV, SUDV, MARV, LASV, hantavirus) https://www.cdc.gov/viral-hemorrhagic-fevers/about/index.html Encephalitic paramyxoviruses (e.g. hendra virus, nipah virus) Picornaviruses (broad spectrum approaches that include EV68, EV70 and coxsackie virus) At least two of the following (i.e., addressed with a broad spectrum antimicrobial): susceptible and carbapenem-resistant Enterobacteriaceae (CRE), susceptible and multidrug resistant (MDR) Pseudomonas aeruginosa, and susceptible and Carbapenem-resistant Acinetobacter (CRAB), with potential to improve patient outcomes in the clinic; Candida auris, Cryptococcus spp., Aspergillus fumigatus, and/or Mucorales Adjunct medical interventions to support or enhance effectiveness of antimicrobial agents to address underlying pathology that is not resolved after clearance of pathogens, may be considered. Important notice to Offerors: For this Research Area, “therapeutic” activity means curing disease by eliminating or substantially reducing infective pathogens by administering antimicrobial pharmaceutical agents, with or without a host-directed therapy. Additionally, proposed therapeutic products should consider the impact on a healthy microbiome. Preventative treatments are not included in the scope of this Research Area. A therapeutic candidate refers to an advanced lead series, preclinical candidates, or a clinical candidate, that is a new chemical entity. This includes small molecules, natural products, nucleosides, or peptides of </= 40 amino acids, monoclonal antibodies, nanobodies, nanobody conjugate/fusion products, microbiome-based therapeutics or bacteriophages. Research Area 002 will support lead optimization, pre-clinical Investigational New Drug (IND) enabling studies, and Phase 1 clinical trials (or proof of concept Phase 2 clinical trials) of lead candidates with demonstrated therapeutic activities. This includes support for traditional, novel (e.g., small molecules) and non-traditional (e.g., including but not limited to phage, and host-directed) therapeutics for infectious diseases where patients lack effective interventions, as well as therapeutics that promote host-mediated resolution of disease. The scope of support differs depending on the developmental stage of the project being proposed, which is further discussed in the BAA Solicitation. Research Area 003 - In Vitro Diagnostics The objective of Research Area 003 is to develop innovative, technology platforms that will speed detection and identification of infectious viruses covering a broad panel of virus families, including viruses causing acute infections as well as those causing chronic infections. Technology platform innovation to achieve faster actionable sequencing results (approaching 2 hr) direct from primary clinical specimens, as well as more accessible workflow and configuration (i.e., point-of-care) are preferred. Furthermore, full sample-to-answer platform solutions are preferred. The system should accept specimen volumes from 0.5 to 5 milliliters (mL). The system should include nearly full automation (little or no hands-on activity after specimen has been loaded into system). Sample preparation components of the system should yield sufficient analyte recovery from a starting titer of 10-100 genomic copies per mL of biofluid for downstream analysis, including detection, identification, and characterization of the nucleic acid material. Innovations during platform development might include, for example: Automated sample prep for high recovery from low pathogen load. Faster specimen-to-answer for total test time <2 hours. Broad viral pathogen detection capability, covering one or more members of the priority pathogen families (see below). Targeted, or even untargeted pathogen detection and identification via long-read sequencing or other detection methods. Multiple specimen throughput per run for reduced cost. Analytical sensitivity approaching 5-50 genome copies per mL of starting biofluid. Assay reconfigurability to respond rapidly to a novel pathogen in days or weeks rather than months (i.e., agnostic diagnostic solution). Priority Pathogens The diagnostic test system must detect analytes from at least one, and preferably several, of the following agents and markers: Arenaviridae (e.g., Lassa virus) Phenuviridae (e.g., Rift Valley fever virus) Peribunyayviridae (e.g., Oropouche virus) Hantaviridae (e.g., Hantavirus) Nairoviridae (e.g., Crimean Congo Hemorrhagic fever virus) Filoviridae (e.g., Sudan virus, Ebola virus, Marburg virus) Flaviviridae (e.g., Hepatitis C virus, West Nile Virus) Paramyxoviridae (e.g., Nipah virus) Togaviridae (e.g., Chikungunya virus) Picornaviridae (e.g., Enterovirus) PROPOSAL SUBMISSION: Proposals Due Date and Time – December 8, 2026, 3:00 PM Eastern Time For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by any other method is not permitted. For directions on using eCPS, go to the website: https://ecps.nih.gov and thenclick on "How to Submit."
48%
Solicitation12/08/2026
NOTICE OF A PROPOSED CONTRACT ACTION NON-COMPETITIVE Notice ID: 75N95022C00004 Contract Opportunity Type: Presolicitation Response Date: November 27, 2026, at 1:00 PM Eastern Time (15 days) Classification: No Small Business Set Aside Used Product Service Code: AN11 NAICS Code: 541715 Place of Performance: Blank Description PURSUANT TO RFO 5.101 — PRESOLICITATION NOTICE, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION. THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022C00004 WITH VIRGINIA COMMONWEALTH UNIVERSITY. THIS IS NOT A SOLICITATION OR A REQUEST FOR COMPETITIVE PROPOSALS. The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), through the Addiction Treatment Discovery Program (ATDP) within NIDA’s Division of Therapeutics and Medical Consequences (DTMC), intends to modify Single Award Contract No. 75N95022C00004, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA,” to extend the period of performance by 12-months through February 21, 2027. All other terms and conditions remain unchanged. This modification will allow for the continuation of ongoing research conducted under the Preclinical Medications Discovery and Abuse Liability Testing program for NIDA and prevent any delays or disruption to the development of therapeutics essential for ongoing and upcoming pre-clinical and clinical trials while a new contract is properly planned and competed. REGULATORY AUTHORITY The resultant modification will include all applicable provisions and clauses of the Revolutionary FAR Overhaul (RFO) Initiative, in accordance with Executive Order 14275 and OMB Memorandum M-25-26. STATUTORY AUTHORITY This modification is conducted under the authority of 41 U.S.C. 3304(a)(1) and in accordance with RFO 6.103-1 Only one responsible source and no other supplies or services will satisfy agency requirements. CLOSING STATEMENT THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by the closing date and time of this announcement and must reference the Project Title, “Preclinical Medications Discovery and Abuse Liability Testing for NIDA.” Responses must be submitted electronically to Shayna Simpson, Contracting Officer, at shayna.simpson@nih.gov. Mailed and faxed responses will not be accepted. PRIMARY POINT OF CONTACT: Shayna Simpson Email: shayna.simpson@nih.gov Phone: 301-402-9712
48%
Pre-Solicitation11/27/2026

Additional Details

Solicitation Number

75N98026Q00914

Archive Date

Aug 25, 2026

Office Address

BETHESDA, MD, 20892